1 / 45

Director’s Report to the National Advisory Council on Drug Abuse

Detailed overview of recent NIDA staff appointments, awards, and initiatives in drug abuse prevention research. Highlights future directions and offers insights into NIDA's major research programs and partnerships.

maeb
Download Presentation

Director’s Report to the National Advisory Council on Drug Abuse

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Director’s Report to the National Advisory Council on Drug Abuse May 22, 2002 (Prepared by Linda Thomas)

  2. Overview of 1st 172 days… 10 hours… 14 minutes… (but who’s counting?)

  3. Recent NIDA Staff Appointments William Corrigall, Ph.D. - Chief, TRB, DNBR and Director, Nicotine and Tobacco Addiction Program Charlotte Annan – OD/SPO Redonna Chandler, Ph.D. – DESPR Dave Daubert – OPRM, MASB Ron A. Dobbins - CCTN Susan E. Martin, Ph.D. – DESPR Bev Pringle, Ph.D. – DESPR Dawn Rabunsky – OPRM, CMB

  4. Recent Staff Awards Dr. Ahmed Elkashef - Physician Research of the Year Award from PHS Commissioned Corps Deborah Wertz – Special Recognition Award Daisey Parker – Letter of Appreciation Diana Haikalis – Letter of Appreciation Debra Battle-Dudley – Letter of Appreciation

  5. Director’s Report to the National Advisory Council on Drug Abuse Highlights of Initiatives and Activities What’s Changing At NIDA? Future Directions

  6. Highlights of NIDA Initiatives and Activities

  7. “Neuroimaging Technology Development to Assess Brain and Behavior in Pediatric Populations” (RFA-DA-02-001) 38 applications

  8. Community Multi-site Prevention Trials Transdisciplinary Prevention Research Centers Basic Science In Prevention Research National Prevention Research Initiative (NPRI)

  9. New NIDA RFAs “NIDA National Prevention Research Initiative: Using Basic Science To Develop New Directions in Drug Abuse Prevention Research” (DA-02-010) 31 applications “NIDA National Prevention Research Initiative: Transdisciplinary Prevention Research Centers” (DA-02-005) 18 applications “Science Education NIDA National Prevention Research Initiative: Community Multi-Site Prevention Trials” (DA-02-004) 5 applications

  10. “National Criminal Justice Drug Abuse Treatment Research System” (RFA-DA-02-011) Issued: February 4, 2002 Application Receipt Date: May 13, 2002 21 Applications

  11. “Expansion of the National Drug Abuse Treatment Clinical Trials Network” (RFA-DA-02-003) 9 applications CTN

  12. “Modifying and Testing Efficacious Behavioral Therapies to Make Them More Community Friendly” (RFA-DA-02-006) 18 applications

  13. “New Approaches to Prevent HIV/Other Infections in Drug Users” (RFA-DA-02-009) 20 applications

  14. “Hepatitis C Diagnosis, Treatment and Interaction with HIV/AIDS” (RFA-DA-02-008) 34 applications

  15. Satellite Sessions for the XIV International AIDS Conference Youth Drug Abuse and HIV Infection in Cultural Context Impact of Health Disparities on HIV Interventions in Drug- Using Populations Drug Abuse Treatment as HIV Prevention Effects of Drug Abuse and Sex Work on HIV Prevention Across National Borders HIV Risk Among Transgenders: The Social and Cultural Context of Substance Abuse Clarifying the Controversy About Whether Drug Abuse Influences AIDS Progression The Global Research Network on HIV Prevention in Drug- Using Populations Psychostimulant Abuse and HIV Risk

  16. Released March 2002 • Summary: • Prevention principles • Frequently asked questions • Epidemiology • NIDA’s major research programs

  17. “Inhalant Abuse: Supporting Broad-Based Research Approaches” (RFA-DA-02-002) 30 applications

  18. 10th Annual National Inhalants and Poisons Awareness Week (NIPAW) Press Conference Participants (Mar. 13, 2002): NIDA – Dr. David Shurtleff ONDCP – John Walters SAMHSA – Charles Curie CSAT – Westley Clark CSAP – Elaine Parry Partnership for a Drug Free America – Stephen Pasierb National Inhalant Prevention Coalition – Harvey Weiss

  19. New NIDA PAs “Science Education Drug Abuse Partnership Award” (PA-02-070) “Neuroscience Research on Drug Addiction” (PA-02-085) “Chemistry, Pharmacology, and Toxicology of Smoked Drugs of Abuse” (PA-02-095) “Imaging – Science Track Award For Research Transition (I/START)” (PAR-02-058)

  20. New PAs With Other NIH Components “Identifying Functional Links Between the Immune System and Brain Function Including Behavior” (PA-02-045) “Dissertation Research Grants for Underrepresented Minorities in the Ethical, Legal, and Social Implications (ELSI) of Genetic Research” (PA-02-048) “Transitional Research Grants in Behavioral Science” (PA-02-061) “Building Translational Research in Behavioral Science” (PAR-02-062) “Methodology and Measurement in the Behavioral and Social Sciences” (PAR-02-072) “Innovative Toxicology Models: SBIR/STTR” (PA-02-075) “Mentored Clinical Scientists Development Program Award” (K12 AWARD) (PAR-02-076)

  21. New RFAs With Other NIH Components “Human Subjects Research Enhancements Program” (RFA-OD-02-003) “Large-Scale Genotyping for the Haplotype Map of the Human Genome” (RFA-HG-02-005) “Genetics in HIV/CNS Disease: Implications for Pathogenesis” (RFA-MH-02-012)

  22. NIH Extramural Loan Repayment Program Regarding Clinical Researchers Educational loan repayment programs (LRP) for Clinical, Pediatric, Contraceptive and Infertility, and Health Disparities Researchers from a Disadvantaged Background

  23. We’ll Be Talking More About This Topic This Afternoon… NIH Extramural Loan Repayment Program Regarding Clinical Researchers Purpose:Recruitment and retention of highly qualified health professionals as clinical investigators; Participants contractually agree to engage in clinical research as extramural grantees or awardees (NIDA-26; NIH- >600) Provides for the repayment of up to $35,000 of awardees’ loans for each year of obligated service

  24. Highlights of Recent Meetings and Events

  25. 7th Annual PRISM AWARDS May 9, 2002 Sponsored by: EIC NIDA RWJ

  26. Other Recent Meetings/Events “Strategies to Improve the Replicability, Sustainability, and Durability of HIV Prevention Interventions for Drug Users” Special Events Program (at the Society for Research on Adolescence) “Cardiovascular Complications of HIV (& Substance Abuse)” HIV/AIDS, Viral Hepatitis and Addiction: Perspectives on Prevention and Treatment” (at ASAM Meeting) “Lapse and Relapse: The Chronic, Recurring Nature of Drug Addiction” “Mental Health Research Issues in HIV Infection and Aging”

  27. Meetings Continued • Enhancing Outcomes in Women’s Health

  28. Coming Soon… Objective: -enhance practical use of research and rapid adaptation into drug abuse treatment

  29. What Is Changing at NIDA? NORMAL Redefined

  30. Changes in Expectations Administration Congress Communities TRANSLATION & ACCOUNTABILITY

  31. Changes in Relationships ONDCP SAMHSA Other NIH Institutes (particularly NIAAA, NIMH, NINDS)

  32. ONDCP NIH NIDA Define Common Science Issues NIAAA, NIMH, NINDS, etc. Medications Development CTN SAMHSA ATTC Goal: to decrease drug abuse by 10% in 2 yrs. & 25% in 5 yrs. DO SCIENCE TEST SCIENCE MOVE SCIENCE INTO COMMUNITIES

  33. Future Directions

  34. PHYSIOLOGICAL HISTORICAL - genetics- circadian rhythms- disease states- gender - previous history- expectation- learning DRUGS ENVIRONMENTAL - social interactions- stress- conditioned stimuli BRAIN MECHANISMS We Need to Study the Effects of All of These Factors & Their Interactions in the Development, Progression & Treatment of Drug Abuse and Addiction BEHAVIOR ENVIRONMENT

  35. Neuroscience and Behavioral Research Initiatives Neuroproteomics Mapping Functional Circuits in the Brain Neural Plasticity and Long Term Changes Protein Trafficking Novel Drug Development Stress & Drug Abuse Drug Abuse Relapse Social Cognitive Neuroscience HIV/AIDS

  36. Epidemiology, Prevention and Services Research Epidemiology Develop frameworks to identify environmental risk factors & gene-environment interactions Examine biological predictors of drug use/abuse Examine proximal influences to drug abuse Determine drug abuse trends in underserved areas Prevention Test interventions targeted to specific high-risk populations Test delivery models & systems for identification & intervention with a wide range of problem clusters

  37. Epidemiology, Prevention and Services Research (continued) Services Develop laboratories for blending research & practice in different settings Test treatment and recovery models which account for the chronic illness concept Test alternative models for treating criminal justice- involved drug abusers Determine which components of the treatment delivery systems are effective for adolescent drug abusers

  38. Treatment Research and Development Develop and screen new compounds active at novel sites Increase collaboration with other NIH ICs and pharmaceutical companies for medication development Immunotherapy Guidance and retraining models for counselors and therapists

  39. CTN Expansion • Additional Nodes • RFA 2002 • Military nodes • “Developing” Nodes? • Additional Sites • CTPs with special features • As needed

  40. CAMCODA TOPICS • CAMCODA • Street youth • Social and disease related • Counseling and Testing • Does it work well? • Trans NIDA • International Research • Rural • Drug driven epidemics • Hepatitis C • Treatment issues • Disabled populations • Physically disabled • Mentally disabled • Developmentally disabled

  41. Future Directions We Want FEEDBACK!

  42. We Want Feedback On Philosophy What we should be doing What we should not be doing Proposed Initiatives

More Related